Nurix Therapeutics, Inc.
NRIXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of. At a $2.40B market cap, Nurix Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Market Cap
$2.40B
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-10.45
EPS (TTM)
$-3.46
EPS (Fwd)
$-2.21
ROE
-80.3%
ROA
-40.1%
Cash
$443.5M
Total Debt
$58.1M
Free CF
-$164.6M
52W Change
106.2%
Annual Financials
Cash vs Debt
With $443.5M in cash and $58.1M in debt, NRIX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$164.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $38.6M (2022) to $84.0M (2025), reflecting a 117% increase over the period.
A beta of 1.80 means NRIX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nurix Therapeutics, Inc. and its sector.